Project Grant R01AR088074
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (part of the National Institutes of Health) awarded the University of California, Los Angeles $150,152 on March 27, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize migratory cell differentiation in developing zebrafish skin. The research will use live imaging, antibody staining, single-cell RNA sequencing, and pseudotime analysis to characterize the development of...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, San Diego $559,827 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms regulating inflammatory responses in epidermal keratinocytes. The research will characterize the role of the ZNF750 protein complex and its associated factors (KDM1A/LSD1, SETDB1, TRIM28/KAP1, and HNRNPU) in mediating...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University $148,062 on September 30, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research investigates the mechanism by which epithelial stem and progenitor cells encode inflammatory memory in psoriasis and other remitting-relapsing inflammatory disorders. The study tests whether homeostatic and inflammatory transcription factors dynamically...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded University of California Irvine $249,000 on February 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for Project Grant R00AR083536. The award funds research to decode the repair and immunomodulatory functions of lymphatic vessels in wound healing. The research aims to delineate mechanisms and consequences of lymphatic vessel remodeling during skin repair and to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California at Riverside $224,100 on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate epigenetic factors controlling epidermal stem cell longevity in adult skin. The research examines how epigenetic regulators, specifically polycomb repressive complexes, function in hair follicle stem cells and interfollicular...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Pennsylvania $2,063,666 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate protein translation efficiency in T cell adaptation to human skin. The research addresses tissue-resident memory T cells (TRM) that persist in skin despite current immunosuppressive treatments and drive chronic inflammatory and autoimmune skin disease. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, awarded The Rockefeller University $100,228 on November 27, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate whether embryonic exposure to hypoxia primes epidermal stem cells for inflammatory response in postnatal life. The research tests the hypothesis that developmental transcription factor activity, specifically...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Leland Stanford Junior University $204,682 on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize the roles of RNA-binding protein assemblies in epidermal homeostasis. The recipient will develop and apply two new crosslinking immunoprecipitation-based methods—IRCLIP-RNP and RE-CLIP—to study how RNA-binding proteins organize and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $581,451 to Icahn School of Medicine at Mount Sinai on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate neuroimmune mechanisms underlying pruritus and microbiota-evoked sensory nerve hyperinnervation. The research examines how commensal microbiota-induced immune responses, particularly T cell immunity to Staphylococcus aureus and IL-17A cytokine...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, Los Angeles $368,156 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop UGIGEL, a gelatin-based, self-healing bioadhesive for chronic wound treatment. The award funds research to engineer and optimize UGIGEL through a one-pot Ugi four-component reaction combining gelatin, 4-formylphenylboronic acid, gallic acid, and...
The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, Los Angeles $493,148 on September 3, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize mechanisms of intra-epithelial migration in the developing epidermis. The project uses live imaging of developing zebrafish to investigate how specialized cell types arising from basal epidermal cells—specifically mucus-secreting cells and ion-transporting cells—migrate through the intra-epithelial space, integrate into the superficial epithelium, and differentiate. The research addresses a gap in understanding how cells disperse and distribute widely through epithelial tissues including the skin, cornea, mouth lining, gut, lung, kidney, inner ear, prostate, and bladder. Prior work in zebrafish revealed that mucus-secreting cell and ion-transporting cell precursors originate from basal epidermal cells in the ventral embryo and migrate within the intra-epithelial space, but the mechanisms governing this migration remain undocumented. The study extends existing knowledge of cell migration through extracellular matrix-rich environments to the understudied context of ECM-poor epithelia. UCLA's Office of Research Administration serves as the recipient. Performance occurs in Los Angeles, California. The award runs from September 3, 2026, through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $493.1k | 9/3/26 |